A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

BACKGROUND: This phase I, open-label, dose-escalation study evaluated the safety, pharmacokinetics and pharmacodynamics of combination therapy with the HDM2 inhibitor SAR405838 and the MEK1/2 inhibitor pimasertib administered orally once daily (QD) or twice daily (BID) in locally advanced or metasta...

Descripción completa

Detalles Bibliográficos
Autores principales: de Weger, Vincent A., de Jonge, Maja, Langenberg, Marlies H. G., Schellens, Jan H. M., Lolkema, Martijn, Varga, Andrea, Demers, Brigitte, Thomas, Koruth, Hsu, Karl, Tuffal, Gilles, Goodstal, Samantha, Macé, Sandrine, Deutsch, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354023/
https://www.ncbi.nlm.nih.gov/pubmed/30585255
http://dx.doi.org/10.1038/s41416-018-0355-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354023/
https://www.ncbi.nlm.nih.gov/pubmed/30585255
http://dx.doi.org/10.1038/s41416-018-0355-8

Ejemplares similares